GekkoVet and Royal Canin to expand AI vet tool worldwide after pilot success
Royal Canin, part of Mars Incorporated, develops nutritional products for cats and dogs and was founded in 1968 by French veterinarian Jean Cathary
Register to get 1 more free article
Reveal the article below by registering for our email newsletter.
Want unlimited access? View Plans
Already have an account? Sign in
Finnish health technology company GekkoVet and pet nutrition group Royal Canin are set to expand their collaboration worldwide after a pilot programme found strong support for the use of artificial intelligence in veterinary decision-making.
The companies said 92% of veterinarians taking part in the trial reported that GekkoVet’s software improved efficiency and had a positive impact on clinic revenue.
The platform combines four tools, diagnosing assistance, a disease and treatment library, a drug library, and a drug calculator, to help clinicians make faster, evidence-based decisions.
The global rollout is scheduled to begin in the fourth quarter of 2025, with full expansion into all markets expected in 2026.
Johanna Majamaa, chief executive of GekkoVet, said the partnership reflected a “shared vision of supporting veterinarians with intelligent tools that enhance clinical decision-making and elevate the standard of care”.
Brent Mayabb, global chief medical officer at Royal Canin, said: “We believe in empowering veterinary teams with the best tools available. GekkoVet’s platform aligns with our mission to advance pet health through science and partnership.”
GekkoVet, founded in Finland, provides AI-powered clinical decision support used by veterinary clinics internationally. Royal Canin, part of Mars Incorporated, develops nutritional products for cats and dogs and was founded in 1968 by French veterinarian Jean Cathary.
